BTX-A51

Phase 1Small molecule

EEdgewood Oncology Inc.

BTX-A51 is one of 124 small molecule programs targeting Liposarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

LiposarcomaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Breast CancerActive, not recruiting

LiposarcomaPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Trodelvy

Gilead

Preclinical

37 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

Megace

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Myelodysplastic Syndrome

NCT04243785

Q2 2027

Phase 1Recruiting

Breast Cancer

NCT04872166

Phase 1Active, not recruiting

Liposarcoma

NCT06414434

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting·EEdgewood Oncology Inc.·Phase 1·NCT04243785·80 enrolled

Breast Cancer1 trial

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Recruiting·EEdgewood Oncology Inc.·Phase 1·NCT04872166·112 enrolled

Liposarcoma1 trial

A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications, Myxoid Liposarcoma, and CIC-Rearranged Sarcoma

Active, not recruiting·MMichael Wagner, MD·Phase 1·NCT06414434·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BTX-A51. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BTX-A51 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BTX-A51. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Edgewood Oncology Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEdgewood Oncology Inc.

BTX-A51

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Breast Cancer1 trial

Liposarcoma1 trial

References

Drug Info

Quick Facts

Related News